Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study
(1)
,
(2)
,
(3, 4)
,
(5)
,
(6)
,
(7)
,
(8, 9)
,
(1)
,
(10)
,
(11)
,
(12)
,
(13)
,
(11)
,
(14)
,
(11)
,
(15)
,
(16)
,
(17)
,
(18)
,
(19)
,
(20)
,
(21, 22)
,
(23)
,
(24)
,
(25)
,
(26)
,
(27, 28)
,
(29)
,
(30)
,
(31, 32)
,
(33)
,
(34)
,
(35)
,
(36)
,
(1)
,
(37, 38)
,
(4, 39)
,
(40)
,
(40)
,
(41)
,
(41, 42)
,
(43)
,
(44)
,
(45)
,
(46)
,
(47)
,
(32)
,
(48)
,
(49)
,
(50)
,
(11)
,
(1)
,
(4)
,
(4, 51)
,
(11)
,
(1)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
Daniel Barrowdale
- Function : Author
- PersonId : 768869
- ORCID : 0000-0003-1661-3939
Jacques Simard
- Function : Author
- PersonId : 757778
- ORCID : 0000-0001-6906-3390
Anna Jakubowska
- Function : Author
- PersonId : 762556
- ORCID : 0000-0002-5650-0501
Abstract
Background: For BRCA1 and BRCA2 mutation carriers, the association between oral contraceptive preparation (OCP) use and breast cancer (BC) risk is still unclear.
Methods: Breast camcer risk associations were estimated from OCP data on 6030 BRCA1 and 3809 BRCA2 mutation carriers using age-dependent Cox regression, stratified by study and birth cohort. Prospective, left-truncated retrospective and full-cohort retrospective analyses were performed.
Results: For BRCA1 mutation carriers, OCP use was not associated with BC risk in prospective analyses (hazard ratio [HR] = 1.08, 95% confidence interval [CI] = 0.75 to 1.56), but in the left-truncated and full-cohort retrospective analyses, risks were increased by 26% (95% CI = 6% to 51%) and 39% (95% CI = 23% to 58%), respectively. For BRCA2 mutation carriers, OCP use was associated with BC risk in prospective analyses (HR = 1.75, 95% CI = 1.03 to 2.97), but retrospective analyses were inconsistent (left-truncated: HR = 1.06, 95% CI = 0.85 to 1.33; full cohort: HR = 1.52, 95% CI = 1.28 to 1.81). There was evidence of increasing risk with duration of use, especially before the first full-term pregnancy (BRCA1: both retrospective analyses, P < .001 and P = .001, respectively; BRCA2: full retrospective analysis, P = .002).
Conclusions: Prospective analyses did not show that past use of OCP is associated with an increased BC risk for BRCA1 mutation carriers in young middle-aged women (40-50 years). For BRCA2 mutation carriers, a causal association is also not likely at those ages. Findings between retrospective and prospective analyses were inconsistent and could be due to survival bias or a true association for younger women who were underrepresented in the prospective cohort. Given the uncertain safety of long-term OCP use for BRCA1/2 mutation carriers, indications other than contraception should be avoided and nonhormonal contraceptive methods should be discussed.
Domains
Life Sciences [q-bio]
Origin : Publication funded by an institution